Effect of Aspirin at the Acute Phase of Cerebral Ischemic Event.
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Aspirin is the only anti-platelet medication used at the acute phase of ischemic stroke. The
investigators would like to study laboratory effect of the first oral 300 mg dose of aspirin,
given at hospital, after an ischemic event.
The principal hypothesis is that platelet activity would be able to recover during this day
and could lead to ischemic recurrences.
Two blood samples are accomplished. The first 2 hours after aspirin intake and the second 23
hours after. Photometric aggregometry are performed with arachidonic acid and collagen
induced platelet aggregation, measure of thromboxan B2 levels and reticular platelets count.